益丰药房：业绩稳健增长，各区域门店扩张持续推进

Investment Rating - The report maintains a "Buy" rating for the company [1][2][3] Core Views - The company has demonstrated steady revenue and profit growth, with a year-on-year revenue increase of 8.38% to RMB 17.219 billion and a net profit increase of 11.14% to RMB 1.111 billion for the first three quarters of 2024 [2][3] - All regions have shown stable revenue growth, with both wholesale and retail businesses maintaining positive growth [3] - The company continues to expand its store network, adding 2,254 new stores in the first nine months of 2024, bringing the total to 15,050 stores [3] Financial Summary - For Q3 2024, the company achieved a revenue of RMB 5.456 billion, a 5.31% increase year-on-year, and a net profit of RMB 313 million, up 6.38% year-on-year [3] - The gross margin for Q1-Q3 2024 was 40.39%, an increase of 0.84 percentage points year-on-year, while Q3 2024 gross margin was 41.13%, up 2.50 percentage points year-on-year [3] - Revenue projections for 2024, 2025, and 2026 are RMB 26.051 billion, RMB 31.779 billion, and RMB 38.654 billion, respectively, with corresponding net profits of RMB 1.677 billion, RMB 2.036 billion, and RMB 2.512 billion [4][3]